Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000899243-18-001348

Chief Legal Officer sold 66,000 shares at an average $28.03 ($1,850,255)

  • Chief Legal Officer acquired 21,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Dylan-Hyde Tyler Chief Legal Officer 2018-01-16 Sale −45,000 $28.00 $1,260,000 25,204 D
Dylan-Hyde Tyler Chief Legal Officer 2018-01-16 Option exercise +1,110 $12.57 $13,953 26,314 D
Dylan-Hyde Tyler Chief Legal Officer 2018-01-16 Sale −1,110 $28.24 $31,346 25,204 D
Dylan-Hyde Tyler Chief Legal Officer 2018-01-16 Option exercise +19,890 $12.57 $250,017 45,094 D
Dylan-Hyde Tyler Chief Legal Officer 2018-01-16 Sale −19,890 $28.10 $558,909 25,204 D
Derivatives
Dylan-Hyde Tyler Chief Legal Officer 2018-01-16 Option exercise · Stock Option (Right to Buy) −1,110 36,663 D
Dylan-Hyde Tyler Chief Legal Officer 2018-01-16 Option exercise · Stock Option (Right to Buy) −19,890 5,237 D
Open-market sales · 66,000 sh · avg $28.03 · $1,850,255
Loading xslF345X03/doc4.xml…